Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mandy Beyer

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Tropical Medicine & International Health : TM & IH|March 12, 2011
Rotavirus and norovirus infections in children in Sana'a, YemenAndrew Kirby, Ali Al-Eryani, Najla Al-Sonboli, et al.
Cell Chemical Biology|November 11, 2021
Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cellsMandy Beyer, Sven J Henninger, Patricia S Haehnel, et al.
Journal of Medicinal Chemistry|March 29, 2018
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 InhibitorsAndreas Sellmer, Hubert Stangl, Mandy Beyer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 4, 2016
MK2/3 Are Pivotal for IL-33-Induced and Mast Cell-Dependent Leukocyte Recruitment and the Resulting Skin InflammationSebastian Drube, Florian Kraft, Jan Dudeck, et al.
European Journal of Medicinal Chemistry|March 22, 2020
A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemiaAndreas Sellmer, Bernadette Pilsl, Mandy Beyer, et al.
Archives of Toxicology|October 19, 2021
Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3Vanessa Wachholz, Al-Hassan M Mustafa, Yanira Zeyn, et al.
Oncogene|September 6, 2022
Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibitionRené Winkler, Ann-Sophie Mägdefrau, Eva-Maria Piskor, et al.
Cellular Signalling|November 14, 2016
Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cellsClaudia Schäfer, Anja Göder, Mandy Beyer, et al.
Oncotarget|March 10, 2015
Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cellsSebastian Drube, Franziska Weber, Romy Loschinski, et al.
Molecular Oncology|July 14, 2021
Mechanistic insights into p53-regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cellsChristian Marx, Jürgen Sonnemann, Mandy Beyer, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Tropical Medicine & International Health : TM & IH|March 12, 2011
Rotavirus and norovirus infections in children in Sana'a, YemenAndrew Kirby, Ali Al-Eryani, Najla Al-Sonboli, et al.
Cell Chemical Biology|November 11, 2021
Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cellsMandy Beyer, Sven J Henninger, Patricia S Haehnel, et al.
Journal of Medicinal Chemistry|March 29, 2018
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 InhibitorsAndreas Sellmer, Hubert Stangl, Mandy Beyer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 4, 2016
MK2/3 Are Pivotal for IL-33-Induced and Mast Cell-Dependent Leukocyte Recruitment and the Resulting Skin InflammationSebastian Drube, Florian Kraft, Jan Dudeck, et al.
European Journal of Medicinal Chemistry|March 22, 2020
A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemiaAndreas Sellmer, Bernadette Pilsl, Mandy Beyer, et al.
Archives of Toxicology|October 19, 2021
Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3Vanessa Wachholz, Al-Hassan M Mustafa, Yanira Zeyn, et al.
Oncogene|September 6, 2022
Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibitionRené Winkler, Ann-Sophie Mägdefrau, Eva-Maria Piskor, et al.
Cellular Signalling|November 14, 2016
Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cellsClaudia Schäfer, Anja Göder, Mandy Beyer, et al.
Oncotarget|March 10, 2015
Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cellsSebastian Drube, Franziska Weber, Romy Loschinski, et al.
Molecular Oncology|July 14, 2021
Mechanistic insights into p53-regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cellsChristian Marx, Jürgen Sonnemann, Mandy Beyer, et al.
Pageof 2